A Novel Monoclonal Antibody Induces Cancer Cell Apoptosis and Enhances the Activity of Chemotherapeutic Drugs

  • Xu, Heng (Institute of Translational Medicine, School of Pharmaceutical Sciences, Nanjing Tech University) ;
  • Tian, Yan-Na (Jinfiniti Biosciences LLC) ;
  • Dun, Bo-Ying (Jinfiniti Biosciences LLC) ;
  • Liu, Hai-Tao (Jinfiniti Biosciences LLC) ;
  • Dong, Guang-Kuo (Jinfiniti Biosciences LLC) ;
  • Wang, Jin-Hua (Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Georgia Regents University) ;
  • Lu, Shang-Su (Institute of Translational Medicine, School of Pharmaceutical Sciences, Nanjing Tech University) ;
  • Chen, Bo (Institute of Translational Medicine, School of Pharmaceutical Sciences, Nanjing Tech University) ;
  • She, Jin-Xiong (Institute of Translational Medicine, School of Pharmaceutical Sciences, Nanjing Tech University)
  • Published : 2014.06.15


A novel monoclonal antibody (mAb), known as AC10364, was identified from an antibody library generated by immunization of mice with human carcinoma cells. The mAb recognized proteins in lysates from multiple carcinoma cell lines. Cell cytotoxicity assays showed that AC10364 significantly inhibited cell growth and induced apoptosis in multiple carcinoma cell lines, including Bel/fu, KATO-III and A2780. Compared with mAb AC10364 or chemotherapeutic drugs alone, the combination of mAb AC10364 with chemotherapeutic drugs demonstrated enhanced growth inhibitory effects on carcinoma cells. These results suggest that mAb AC10364 is a promising candidate for cancer therapy.


Supported by : National Science Foundation of China


  1. Attard G, Kitzen J, Blagden S, et al (2007). A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. Br J Cancer, 97, 1338-43.
  2. Chao MP, Alizadeh AA, Tang C, et al (2010). Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell, 142, 699-713.
  3. Crescence L, Beraud E, Sbarra V, et al (2012). Targeting a novel onco-glycoprotein antigen at tumoral pancreatic cell surface by mAb16D10 induces cell death. J Immunol, 189, 3386-96.
  4. de Weers M, Tai YT, van der Veer MS, et al (2011). Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol, 186, 1840-8.
  5. Estevez LG, Martin M, Alba E, et al (2007). Current controversies in the management of early breast cancer. Clin Transl Oncol, 9, 375-84.
  6. Gallamini A, Zaja F, Patti C, et al (2007). Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood, 110, 2316-23.
  7. Hernandez AM, Rodriguez N, Gonzalez JE, et al (2011). Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism. J Immunol, 186, 3735-44.
  8. Giansanti V, Torriglia A, Scovassi AI (2011). Conversation between apoptosis and autophagy:"Is it your turn or mine?". Apoptosis, 16, 321-33.
  9. Gorter A, Meri S (1999). Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today, 20, 576-82.
  10. Grillo-Lopez AJ, Hedrick E, Rashford M, et al (2002). Rituximab: ongoing and future clinical development. Paper presented at: Seminars in oncology (Elsevier).
  11. Jiang L, Hao JL, Jin ML, et al (2013). Effect of embelin on TRAIL receptor 2 mAb-induced apoptosis of TRAIL-resistant A549 non-small cell lung cancer cells. Asian Pac J Cancer Prev, 14, 6115-20.
  12. Loo D, Pryer N, Young P, et al (2007). The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo. Mol Cancer Ther, 6, 856-65.
  13. Majno G, Joris I (1995). Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol, 146, 3.
  14. Maloney D (2003). Rituximab for follicular lymphoma. Curr Hematol Rep, 2, 13.
  15. Parren PW, van de Winkel JG (2008). An integrated science-based approach to drug development. Curr Opin Immunol, 20, 426-30.
  16. Saltz LB, Meropol NJ, Loehrer PJ, et al (2004). Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol, 22, 1201-8.
  17. Scott AM, Wolchok JD, Old LJ (2012). Antibody therapy of cancer. Nat Rev Cancer, 12, 278-87.
  18. Willingham SB, Volkmer JP, Gentles AJ, et al (2012). The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA, 109, 6662-7.
  19. Thornberry NA, Lazebnik Y (1998). Caspases: enemies within. Science, 281, 1312-6.
  20. Tyas L, Brophy VA, Pope A, et al (2000). Rapid caspase-3 activation during apoptosis revealed using fluorescence-resonance energy transfer. EMBO Rep, 1, 266-70.
  21. Weiner LM, Murray JC, Shuptrine CW (2012). Antibody-based immunotherapy of cancer. Cell, 148, 1081-4.
  22. Xu G, Wen X, Hong Y, et al (2011). An anti-transferrin receptor antibody enhanced the growth inhibitory effects of chemotherapeutic drugs on human glioma cells. Int Immunopharmacol, 11, 1844-9.
  23. Yip YL, Ward RL (2002). Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines. Cancer Immunol Immun, 50, 569-87.
  24. Zhang G, Zhang H, Wang Q, et al (2010). Suppression of human prostate tumor growth by a unique prostate-specific monoclonal antibody F77 targeting a glycolipid marker. Proc Natl Acad Sci USA, 107, 732-7

Cited by

  1. Preparation and Characterization of Anti-GP73 Monoclonal Antibodies and Development of Double-antibody Sandwich ELISA vol.16, pp.5, 2015,
  2. EHHM, a novel phenolic natural product from Livistona chinensis, induces autophagy-related apoptosis in hepatocellular carcinoma cells vol.12, pp.5, 2016,